House
Sign inCreate account
Drug lookup
Drug reference

ado-trastuzumab emtansine

HER2-targeted antibody · null

HER2-targeted antibodynullATC null
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
X
FDA category + note

Mechanism

Ado-trastuzumab emtansine targets human epidermal growth factor receptor 2 (HER2) in cancers with HER2 amplification or overexpression.

Indications

breast cancer (HER2 amplification; HER2 overexpression)gastric cancer (HER2 amplification; HER2 overexpression)HER2-positive breast cancer

Side effects

Serious
  • cardiac dysfunction
  • hepatotoxicity
  • bone marrow suppression

Pregnancy & lactation

Pregnancy

X

Related guidelines

Breast cancer
ESMO · Oncology · 2024
Breast cancer
ICMR · Oncology · 2022
Cervical cancer screening and management
ICMR · Oncology · 2022
Tobacco-related cancer prevention
ICMR · Oncology · 2021
Gastric premalignant conditions
ACG · Gastroenterology · 2025

Ask House about ado-trastuzumab emtansine

Continue into a citation-backed clinical answer with the drug context already attached.

Open in workspaceAsk House about this drug

Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team